JBIO: JADE101 shows best-in-class promise for IgA nephropathy, with pivotal trials and broad expansion ahead
The team presented a robust pipeline targeting autoimmune diseases, highlighting JADE101's best-in-class potential in IgA nephropathy with strong phase I data and a rapid path to pivotal trials. Market opportunity is significant, with expansion plans into other indications and strong financial back…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.